Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare data company with 130K connected physicians; EHR-connected real-world evidence network for pharma analytics rebranded from Allscripts competing with IQVIA for life sciences data.
Veradigm (formerly Allscripts Healthcare) is a healthcare information technology company providing EHR-connected data network services, physician practice management software, pharmacy solutions, and life sciences data analytics — operating at the intersection of clinical care delivery and healthcare data commercialization. Listed on NASDAQ (NASDAQ: MDRX) and headquartered in Chicago, Illinois, Veradigm rebranded from Allscripts in 2023 as it refocused from clinical EHR software toward data and analytics services, generating approximately $600 million in annual revenue.\n\nVeradigm's core asset is its network of approximately 130,000 connected physicians and tens of millions of de-identified patient records accessible through its data products. The Veradigm Network connects ambulatory physician practices running Allscripts EHR (Professional EHR, TouchWorks) and enables data flows for prescription analytics, clinical decision support, and real-world evidence (RWE) for pharmaceutical companies. The life sciences data business provides pharma clients with prescription analytics, patient journey data, and clinical research data services.\n\nIn 2025, Veradigm is in strategic transition — the company has been exploring alternatives to maximize shareholder value, including potential sale or acquisition, following activist investor pressure. The EHR product portfolio (Allscripts-branded physician practice software) competes with athenahealth, Epic, and eClinicalWorks in the ambulatory market, though Veradigm's focus has shifted toward its data network value rather than competing head-to-head in EHR functionality. Veradigm competes with IQVIA, Komodo Health, and Definitive Healthcare for life sciences real-world data. The 2025 strategy focuses on growing the data analytics and real-world evidence business while managing the legacy EHR product base.
Largest US pharmaceutical distributor with $308.9B FY2024 revenue; thin-margin distribution triopoly with Cencora and Cardinal Health; US Oncology Network (1,700+ oncologists) is highest-margin segment.
McKesson Corporation is the largest pharmaceutical distributor in North America and a leading healthcare services company, founded in 1833 in New York City by John McKesson and Charles Olcott and now headquartered in Irving, Texas, trading on NYSE (MCK). The company reported approximately $308.9 billion in revenues for fiscal year 2024 (ending March 31, 2024) under CEO Brian Tyler, making it one of the highest-revenue companies in the United States—though the vast majority of revenues represent pass-through pharmaceutical product costs distributed to approximately 40,000 pharmacies, health systems, and medical providers across North America. McKesson operates through four segments: U.S. Pharmaceutical (the dominant distribution engine), Prescription Technology Solutions (pharmacy benefits technology including CoverMyMeds e-prior authorization), Medical-Surgical Solutions (physician office and extended care medical supply distribution), and International (primarily Canadian distribution through McKesson Canada).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.